%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Tang, M. W.
%A Rhee, S. Y.
%A Bertagnolio, S.
%A Ford, N.
%A Holmes, S.
%A Sigaloff, K. C.
%A Hamers, R. L.
%A de Wit, T. F. R.
%A Fleury, H. J.
%A Kanki, P. J.
%A Ruxrungtham, K.
%A Hawkins, C. A.
%A Wallis, C. L.
%A Stevens, W.
%A van Zyl, G. U.
%A Manosuthi, W.
%A Hosseinipour, M. C.
%A Ngo-Giang-Huong, Nicole
%A Belec, L.
%A Peeters, Martine
%A Aghokeng Fobang, Avelin
%A Bunupuradah, T.
%A Burda, S.
%A Cane, P.
%A Cappelli, G.
%A Charpentier, C.
%A Dagnra, A. Y.
%A Deshpande, A. K.
%A El-Katib, Z.
%A Eshleman, S. H.
%A Fokam, J.
%A Gody, J. C.
%A Katzenstein, D.
%A Koyalta, D. D.
%A Kumwenda, J. J.
%A Lallemant, Marc
%A Lynen, L.
%A Marconi, V. C.
%A Margot, N. A.
%A Moussa, S.
%A Ndung'u, T.
%A Nyambi, P. N.
%A Orrell, C.
%A Schapiro, J. M.
%A Schuurman, R.
%A Sirivichayakul, S.
%A Smith, D.
%A Zolfo, M.
%A Jordan, M. R.
%A Shafer, R. W.
%T Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy : programmatic implications for countries phasing out stavudine
%D 2013
%L fdi:010060440
%G ENG
%J Journal of Infectious Diseases
%@ 0022-1899
%K HIV-1 ; drug resistance ; mutations ; nucleoside reverse transcriptase ; inhibitor ; NRTI ; stavudine ; d4T ; zidovudine ; AZT ; tenofovir ; TDF ; subtypes
%M ISI:000319474700005
%N 2
%P S70-S77
%R 10.1093/infdis/jit114
%U https://www.documentation.ird.fr/hor/fdi:010060440
%> https://www.documentation.ird.fr/intranet/publi/2013/07/010060440.pdf
%V 207
%W Horizon (IRD)
%X The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available in resource-limited settings, it is critical to identify the cross-resistance patterns associated with first-line stavudine failure. We analyzed HIV-1 resistance mutations following first-line stavudine failure from 35 publications comprising 1,825 individuals. We also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance. Mutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals. Mutations with preferential tenofovir activity, >= two thymidine analog mutations (TAMs) or Q151M, occurred in 22% of individuals. Nevirapine increased the risk of TAMs, K65R, and Q151M. Longer therapy increased the risk of TAMs and Q151M but not K65R. Subtype C and CRF01_AE increased the risk of K65R, but only CRF01_AE increased the risk of K65R without Q151M. Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-line d4T therapy.
%$ 052 ; 050